title: [Stress-limiting effect of zantac in duodenal ulcer bleeding].
abstract: Two randomized groups of patients with ulcerative gastroduodenal hemorrhage were studied. One group of patients with bleeding-accompanied ulcerative disease of the stomach (n = 11) and the duodenum (n = 22) received the routine therapy, another group, including those of the same diseases (n = 9 and n = 22, respectively) had additionally the histamine H2-receptor blocking agent zontac by the following schedule: intravenously, 50 mg thrice a day within the first 3 days, and orally, 150-mg tablets twice a day within the following 3 weeks. Donors (n = 20) served as a control group for the zontac-treated and untreated patients. The stress-limiting effect of zontac was evaluated by the physicochemical parameters of corticosteroid-binding globulin, serum cortisole and insulin concentrations which were measured on days 1, 3, 7, and 14 following the first hemorrhage. In the zontac-treated group, the association constant of the blood cortisole-corticosteroid-binding globulin increased, while the dissociation constant decreased. At the same time the absolute and relative number of sites for binding of cortisole by means of corticosteroid-binding globulin also dropped to the values seen in the group of donors. Zontac caused a reduction in the cortisole/insulin ratio. This all suggests that zontac produces its stress-limiting effect in patients with ulcerative gastroduodenal hemorrhage. Zontac therapy decreased the need for surgical arrest of bleeding by 50% and the average day/bed.
authors.forename: A S
authors.initials: AS
authors.lastname: Ermolov
authors.forename: G V
authors.initials: GV
authors.lastname: Pakhomova
authors.forename: L F
authors.initials: LF
authors.lastname: Tveritneva
authors.forename: P P
authors.initials: PP
authors.lastname: Golikov
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Nikolaeva
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007328:Insulin / Q000097:blood; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D011899:Ranitidine / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D013312:Stress, Physiological / Q000150:complications / Q000188:drug therapy; D014156:Transcortin / Q000378:metabolism
chemical_list: D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D007328:Insulin; D011899:Ranitidine; D014156:Transcortin; D006854:Hydrocortisone
vernacular_title: Stresslimitiruiushchiĭ éffekt zontaka pri iazvennykh gastroduodenal'nykh krovotecheniiakh.